1. China Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Suzhou Novoprotein Scientific Co., Ltd. Class A

Suzhou Novoprotein Scientific Co., Ltd. Class A

SSSE:688137
107.00
CNY
+0.20
(+0.19%)
-1.29EPS
2.52BMarket Cap
Oct 30Next Earn
Suzhou Novoprotein Scientific Co., Ltd. Class A
SSE:688137
(Shanghai Stock Exchange)

Recent

price

107.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.49
0.51
2.56
8.56
4.64
2.15
1.83
2.09
2.17
Revenue per Share
-0.24
-0.12
1.18
3.73
1.59
0.18
-0.78
-1.11
-1.29
Basic EPS, GAAP
-0.18
-0.05
1.22
0.03
-0.59
0.34
-0.45
-1.32
- -
Free Cash Flow per Basic Share
- -
- -
0.01
0.41
- -
0.49
0.5
- -
- -
Dividend per Share
0.02
-0.15
1.96
6.84
31.35
31.19
29.95
28.99
28.58
Book Value per Share
0.01
-0.15
1.96
6.71
31.09
30.92
29.69
28.74
28.33
Tangible Book Value per Share
53
70
70
40
57
71
70
70
70
Basic Weighted Avg Shares
26
36
180
342
265
153
128
146
152
Sales/Revenue/Turnover
-37.47
-17.22
57.73
56.7
42.68
-3.85
-43.43
-45.54
-43.43
Operating Margin (%)
1
1
2
9
20
23
31
30
- -
Depreciation Expense
-12
-8
83
149
91
13
-54
-78
-91
Net Income, GAAP
- -
- -
11.79
15.45
14.56
- -
- -
- -
- -
Effective Tax Rate (%)
-47.62
-23.62
46.18
43.58
34.29
8.38
-42.66
-53.12
-59.67
Profit Margin (%)
-10
-18
76
260
2,071
2,020
1,889
1,786
1,721
Working Capital
- -
- -
11
78
69
59
49
46
41
LT Debt
1
-8
103
360
2,200
2,188
2,102
2,035
1,999
Total Equity
- -
- -
124.08
51.22
6.57
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
149.49
53.5
6.91
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
64.38
7.09
0.59
-2.54
-3.76
-4.43
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
9
9
9
LT Borrowings
- -
- -
- -
LT Finance Leases
46
43
41
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
70
70
70
Market Capitalization
2,811
2,841
2,517

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,855
1,835
1,818
Cash, Cash Equivalents & STI
711
773
835
Accounts Receivable, Net
62
64
61
Inventories
63
71
77
Total Current Liabilities
69
79
97
Payables & Accruals
- -
- -
- -
ST Debt
9
9
9
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
150.57%
-3.19%
Free Cash Flow
- -
-739.41%
192.23%
Net Income, GAAP
- -
-105.25%
42.94%
Sales/Revenue/Turnover
- -
4.69%
14.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
26
34
32
35
128
2025
33
39
- -
35
146
2026
37
41
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
-0.09
-0.13
-0.52
-0.78
2025
-0.17
-0.18
- -
-0.7
-1.11
2026
-0.15
-0.27
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.5
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Suzhou Novoprotein Scientific Co., Ltd. Class A is a China-based biotechnology company engaged in the research, development, manufacture, and commercialization of recombinant proteins, molecular enzymes, and critical upstream raw materials for biopharmaceutical research, in vitro diagnostics, and cell and gene therapies. The company operates across four primary business segments: Target Proteins, Molecular Biology Enzymes, In Vitro Diagnostic Raw Materials, and Contract Research and Development Services. Its product portfolio comprises recombinant target proteins and cytokines, including GMP-grade cell culture cytokines, growth factors, interleukins, chemokines, immune checkpoint proteins, and viral antigens; mRNA synthesis enzymes and molecular reagents, including T7 RNA polymerases, mRNA capping enzymes, Poly(A) polymerases, inorganic pyrophosphatases, RNase inhibitors, reverse transcriptases, high-fidelity PCR and qPCR enzymes, isothermal amplification reagents, and next-generation sequencing library preparation kits; diagnostic raw materials, including specialized diagnostic antibodies, recombinant antigens, and blocking agents for chemiluminescence, ELISA, and lateral flow assays; and gene editing enzymes, including GMP-compliant Cas9, Cas12a, and Cas13 nucleases. The company also provides specialized contract research and development services, encompassing recombinant protein expression and purification across multiple host systems; antibody engineering and screening; directed enzyme evolution; and end-to-end mRNA contract development and manufacturing organization services spanning plasmid preparation, in vitro transcription, lipid nanoparticle encapsulation, and analytical characterization. Suzhou Novoprotein Scientific serves biopharmaceutical manufacturers, in vitro diagnostic companies, contract research organizations, and academic and medical research institutes across mainland China, North America, Europe, and the Asia-Pacific region. In recent developments, the company has expanded its commercial offerings with integrated, clinical-grade mRNA-LNP solutions to support therapeutic mRNA vaccine and drug development, while scaling its GMP-grade industrial manufacturing infrastructure to meet stringent international quality and regulatory standards. Additionally, the company has accelerated its international expansion by establishing strategic distribution partnerships and deepening commercial collaborations with biopharmaceutical and diagnostic developers globally to facilitate supply chain localization and global delivery. Founded in 2009, Suzhou Novoprotein Scientific Co., Ltd. is headquartered in Suzhou, Jiangsu Province, China.